anonymous
Guest
anonymous
Guest
In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to expand Talzenna into a broader prostate…Fact. The BLUE People at this company are Not Good Enough for this company. Complete Split! Soon Spin Offs will come, many changes in the BOD and the usual suspects. Fun Pfizer! Buckle up
Source: Fierce Pharma
Spin Spin Spin